文摘
B-cells are pivotal in pathogenesis of rheumatoid arthritis and are activated via common γ-chain cytokine receptors. Tofacitinib, a JAK inhibitor, inhibits plasmablast development and antibody secretion from naive B-cells. Treatment with tofacitinib may impair immune responses to new antigens. Vaccination against new antigens prior to tofacitinib treatment should be considered. Tofacitinib does not influence the proportion of B-cell subpopulations but their absolute numbers in vivo.